EUVIMED · CrossrefJournal
Liver Cancer
ISSN 2235-1795 · S. Karger AG
Latest articles
Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Comment on the Article “Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study”
Blood-based PAaM score for predicting HCC risk in patients withHBV-related advanced fibrosis receiving nucleos(t)ide analogtherapy
Unexpected Limited Immune Potentiation of Common Multikinase Inhibitors Combined with Immune Checkpoint Blockade in Hepatocellular Carcinoma: Insights from Murine Models
EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?
Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma
Exposure to Poly- and Perfluoroalkyl Substances and Risk of Hepatocellular Carcinoma in Male Patients with Cirrhosis Related to Hepatitis C Virus Infection
Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan
An updated systematic review and meta-analysis of modern radiotherapy techniques for hepatocellular carcinoma
Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease
Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study
The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis
Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma
Reply to “Methodological Concerns in ‘Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma’”
Reply to the Comment on the Article “Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma”
Lenvatinib Added to Nivolumab and Ipilimumab Improves Tumor Control and Progression-Free Survival in Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study
Hepatic Resection versus Stereotactic Body Radiation Therapy as Initial Local Treatment for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis
Erratum
Erratum
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study
The China Paradox in LEAP-012 Trial
Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials
The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis
Modality-Specific and Multilevel Barriers to Curative Treatment for Early-Stage Hepatocellular Carcinoma
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of Systemic Therapies (2020–2025)
Comment on the Article “Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma”
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
Trajectory Modelling of Prognostic Biomarkers Linked to Liver Cancer Risk: A Systematic Review
EUVIMED